
MitoAction Expert Series
Understanding TK2d and the KYGEVVI Approval
<p>Join us for an informative webinar exploring KYGEVVI™ (doxecitine and doxribtimine), the first FDA-approved treatment for thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years.</p> <p>This session will cover:</p> <p>The basics of TK2d, including its genetic cause, symptoms, and how it is diagnosed<br />The impact of TK2d on patients and families<br />An overview of KYGEVVI, including how it works and who may be eligible for treatment<br />Important safety information and what to expect with therapy<br />For full prescribing in...






